Gate2Brain, a Technology Keybox of BBB-Shuttle Peptides

Gate2Brain

G2B therapeutic-peptide shuttle conjugates are new chemical entities, permeable, non-antigenic, stable, receptor-specific, soluble, non-invasive, and cost-effective products that can cross biological barriers (such as the blood-brain barrier).

Unique properties conferred by
Gate2Brain technology

  • 1

    Ability to penetrate barriers. Our peptides cross biological barriers, such as the blood-brain barrier, to bring therapeutic cargoes to their targets.

    1

Gate2Brain
Gate2Brain

  • 2

    Non-antigenicity. Our proprietary peptides are not immunogenic, minimizing the likelihood of immune reactions against G2B therapeutic-peptide shuttle conjugates.

  • 3

    Protease resistance. Our proprietary peptides bear chemical modifications that increase their half-life up to days, maximizing the area-under-the-curve of G2B therapeutic-peptide shuttle conjugates at their biological targets.

    3

Gate2Brain
Gate2Brain

  • 4

    Receptor specificity. Our proprietary peptides cross biological barriers through receptor-mediated transcytosis.

  • 5

    Water solubility. Our proprietary peptides improve the solubility of practically insoluble small molecule cargoes, making them suitable for human administration.

    5

Gate2Brain
Gate2Brain

  • 6

    Non-invasiveness. Our technology allows the administration of therapeutic cargoes by conventional administration routes.

  • 7

    Cost-effectiveness. Our therapeutic-peptide shuttle conjugates can be produced using low cost and easily scalable processes.

    7

Gate2Brain

Gate2Brain, a Technology Keybox of BBB-Shuttle Peptides

G2B therapeutic-peptide shuttle conjugates are new chemical entities, permeable, non-antigenic, stable, receptor-specific, soluble, non-invasive, and cost-effective products that can cross biological barriers (such as the blood-brain barrier).

Gate2Brain

Unique properties conferred by
Gate2Brain technology

  • 1

    Ability to penetrate barriers. Our peptides cross biological barriers, such as the blood-brain barrier, to bring therapeutic cargoes to their targets.

Gate2Brain

  • 2

    Non-antigenicity. Our proprietary peptides are not immunogenic, minimizing the likelihood of immune reactions against G2B therapeutic-peptide shuttle conjugates.

Gate2Brain

  • 3

    Protease resistance. Our proprietary peptides bear chemical modifications that increase their half-life up to days, maximizing the area-under-the-curve of G2B therapeutic-peptide shuttle conjugates at their biological targets.

Gate2Brain

  • 4

    Receptor specificity. Our proprietary peptides cross biological barriers through receptor-mediated transcytosis.

Gate2Brain

  • 5

    Water solubility. Our proprietary peptides improve the solubility of practically insoluble small molecule cargoes, making them suitable for human administration.

Gate2Brain

  • 6

    Non-invasiveness. Our technology allows the administration of therapeutic cargoes by conventional administration routes.

Gate2Brain

  • 7

    Cost-effectiveness. Our therapeutic-peptide shuttle conjugates can be produced using low cost and easily scalable processes.

Gate2Brain
? On December 13h, Gate2Brain will be participating together with Maribel Berges (AFFIRMA BIOTECH SL), Sven Dr. Mulfinger (Dana_positive maternal health), and Diana Ballart (The Smart Lollipop) in the i4kids Closing Event 2022, sharing achievements and failures of entrepreneurs in #pediatric and maternal #healthcare.i4kids

i4kids Closing Event 2022

Texto descripción
WomenStartupAwards, in the "Inspiration" category.WomeninTechSpain

Finalist of Women Startup Awards

GORDON CONFERENCESgate2brain

Gordon Research Conferences

Gate2Brain's retreat 2022Gate2Brain

Gate2Brain’s retreat 2022

BIO EUROPE 2022GATE2BRAIN

Gate2Brain at BIO-EUROPE 2022

Pediatric Innovation Dayi4kids

G2B at Pediatric Innovation Day 2022

Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social